AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)
Status:
COMPLETED
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
This study is intended to assess the safety and anti-tumor activity of AZD4205 at 150 mg once daily in participants with PTCL who have achieved tumor response after first-line systemic therapy (with or without combination radiotherapy) and are ineligible for HSCT assessed by the investigator as ineligible for HSCT or have no plan for HSCT.